financetom
ZBH
financetom
/
Healthcare
/
ZBH
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Zimmer Biomet Holdings, Inc.ZBH
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.

It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups.

The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.

Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Latest News >
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Mar 3, 2025
On Monday, Protagonist Therapeutics, Inc. ( PTGX ) and Takeda Pharmaceutical Co Ltd ( TAK ) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera. Polycythemia vera is a type of blood cancer. It causes your bone marrow to make too many red blood cells. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires...
Costco Wholesale's Strong Revenue Momentum to Persist, Oppenheimer Says
Costco Wholesale's Strong Revenue Momentum to Persist, Oppenheimer Says
Mar 3, 2025
12:00 PM EST, 03/03/2025 (MT Newswires) -- Costco Wholesale's ( COST ) strong revenue momentum is expected to persist amid limited earnings upside potential, Oppenheimer said Monday in a note. Faced with accelerating inflation pressures and tariff risks, we believe the company's superior value proposition and ability to adjust product mix should help drive further market share gains and manage...
Endeavor Shares Fall After Divestment of Three Businesses
Endeavor Shares Fall After Divestment of Three Businesses
Mar 3, 2025
12:03 PM EST, 03/03/2025 (MT Newswires) -- Endeavor (EDR) shares were down almost 12% in recent Monday trading after the company completed its divestment of three sports and events-related businesses to TKO (TKO). Trading volume stood at over 4.3 million shares against a daily average of about 1.7 million. Price: 28.75, Change: -3.84, Percent Change: -11.78 ...
Wells Fargo drops financed emissions target amid ESG rethink
Wells Fargo drops financed emissions target amid ESG rethink
Mar 3, 2025
(This Feb. 28 story has been corrected to change the attribution to Cushing, not Paddy McCully, in paragraph 10) (Reuters) - Wells Fargo ( WFC ) is scrapping its goal of achieving net-zero emissions across its financed portfolio by 2050 as banks rethink their sustainable lending activities. The goals had relied on many factors outside our control such as public...
Copyright 2023-2025 - www.financetom.com All Rights Reserved